Background: Patients, their families and the community suffer a heavy burden when it comes to asthma because it is both common and possibly life-threatening. It has been postulated that arachidonic acid's most prevalent cyclooxygenase metabolite, prostaglandin D2 (PGD2), is a mast cell activation marker in asthma.
Objective: To evaluate association between PGDR-441 polymorphism with risk factors, laboratory characteristics, and severity of asthma in children.
Methods: In this cross-sectional study, Forty Egyptian children were genotyped using allele specific polymerase chain reaction (AS-PCR) to assess single nucleotide polymorphism of PTGDR2 receptors. Selected cases were classified according to GINA guidelines and spirometrically assessed to evaluate pulmonary functions.
Results: There is significant difference between mild, moderate and severe asthma regarding total IgE level(P1<0.001). 68.0% of the studied patients had Homogenous PGDR2(TT) and 32% had Heterozygous PGDR2(TC). There were no statistically significant associations between PGDR2 Polymorphisms and both of asthma risk factors and laboratory characteristics. There was a statistically significant difference between PGDR2 Polymorphisms and bronchial asthma severity of the studied patients. Heterozygous PGDR2 was associated with more severe bronchial asthma.
Conclusion: Our study showed a strong relationship between polymorphism of PTGDR2 receptor and severity of bronchial asthma
